Press Release: Novartis receives positive CHMP -2-

7. AbbVie. AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to

Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory

Skin Disease. Available at:

https://news.abbvie.com/2016-11-14-AbbVies-HUMIRA-Adalimumab-Receives-CHMP-Positive-Opinion-to-Treat-Adolescents-with-Hidradenitis-Suppurativa-a-Chronic-Inflammatory-Skin-Disease

[Last Accessed: November 2026].

8. European Medicines Agency. Biosimilar medicines: Overview. Available at:

https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview

[Last Accessed: November 2026].

9. Garg A, Naik HB, Alavi A, et al. Real-World Findings on the

Characteristics and Treatment Exposures of Patients with Hidradenitis

Suppurativa from US Claims Data. Dermatol Ther (Heidelb). 2023

Feb;13(2):581-594. doi: 10.1007/s13555-022-00872-1.

10. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev

Dis Primers 2020; 6: 18.

11. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe

hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52

results of two identical, multicentre, randomised, placebo-controlled,

double-blind phase 3 trials. Lancet 2023; 401: 747-761.

12. Novartis Cosentyx receives FDA approval for treatment of children and

adolescents with moderate to severe plaque psoriasis [Press release].

Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis

[Last Accessed: November 2026].

13. Novartis Cosentyx receives FDA approval for the treatment of children and

adolescents with enthesitis-related arthritis and psoriatic arthritis.

[Press release]. Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis

[Last Accessed: November 2026].

14. Novartis Cosentyx receives positive CHMP opinion for expanded use in

childhood arthritic conditions. [Press release]. Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions

[Last Accessed: November 2026].

15. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P,

Pascale P, Delicha EM, Pricop L, Mpofu S. "Secukinumab Provides Sustained

Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final

5-Year Efficacy and Safety Results from a Phase 3 Trial". ACR/ARHP 2020

Annual Meeting Abstract. Presented in ACR Open Rheumatology (2020);

CONCL00511.

16. McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG,

Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L, Mpofu S; FUTURE 2

Study Group. "Long-term efficacy and safety of secukinumab in patients

with psoriatic arthritis: 5-year (end of study) results from the phase

III FUTURE 2 study." Lancet Rheumatology. 2020; 2(4): e227--e235.

17. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R,

Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Secukinumab

demonstrates high sustained efficacy and a favourable safety profile in

patients with moderate-to-severe psoriasis through 5 years of treatment

(SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018

Sep;32(9):1507--1514.

18. Novartis receives European approval for Cosentyx(R) as first and only

IL-17A inhibitor for hidradenitis suppurativa. Available at:

https://www.novartis.com/news/media-releases/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa

[Last accessed: November 2026].

19. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting

interleukin-17. Br J Dermatol. 2012;167(4):717--724.

20. Novartis Cosentyx shows clinically meaningful symptom improvements in

patients with hidradenitis suppurativa. [Press release]. Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials

[Last Accessed: November 2026].

21. Novartis receives European Commission approval for Cosentyx(R) in

polymyalgia rheumatica (PMR). [Press release]. Available at:

https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-cosentyx-polymyalgia-rheumatica-pmr

[Last Accessed: November 2026].

22. Novartis. Cosentyx(R) receives FDA approval for pediatric patients aged

12+ with moderate to severe hidradenitis suppurativa. [Press release].

Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa

[Last Accessed: November 2026].

23. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

Available at:

https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf [Last

Accessed: November 2026].

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41

61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

November 13, 2026 13:30 ET (18:30 GMT)